JTZ-951, a HIF-PH inhibitor, shows positive results for treating renal anemia Jan. 10, 2018 No Comments
Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease Jan. 10, 2018 No Comments
Enrollment begins in phase II/III program for Catalyst Biosciences' marzeptacog alfa Jan. 5, 2018 No Comments
FDA grants breakthrough therapy designation to Promacta for first-line use in severe aplastic anemia Jan. 4, 2018 No Comments
Ironwood Pharmaceuticals begins phase II study of IW-1701 in sickle cell disease Dec. 22, 2017 No Comments
BioMarin initiates first phase III study of valoctocogene roxaparvovec for severe hemophilia A Dec. 20, 2017 No Comments
RSS